MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ALKEM LABORATORIES - NATCO PHARMA
ALKEM LABORATORIES vs NATCO PHARMA - Comparison Results
Current Valuations
| ALKEM LABORATORIES | NATCO PHARMA | ALKEM LABORATORIES/ NATCO PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | - | 28.3 | - | View Chart |
| P/BV | x | 10.2 | 4.2 | 241.0% | View Chart |
| Dividend Yield | % | 0.4 | 0.8 | 53.3% |
Financials
 ALKEM LABORATORIES  NATCO PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ALKEM LABORATORIES Mar-16 |
NATCO PHARMA Mar-19 |
ALKEM LABORATORIES/ NATCO PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,589 | 849 | 187.2% | |
| Low | Rs | 1,232 | 557 | 221.2% | |
| Sales per share (Unadj.) | Rs | 417.5 | 573.8 | 72.7% | |
| Earnings per share (Unadj.) | Rs | 56.3 | 176.0 | 32.0% | |
| Cash flow per share (Unadj.) | Rs | 64.7 | 198.2 | 32.6% | |
| Dividends per share (Unadj.) | Rs | 12.70 | 6.25 | 203.2% | |
| Dividend yield (eoy) | % | 0.9 | 0.9 | 101.3% | |
| Book value per share (Unadj.) | Rs | 292.9 | 842.7 | 34.8% | |
| Shares outstanding (eoy) | m | 119.57 | 36.50 | 327.6% | |
| Bonus/Rights/Conversions | - | BB | - | ||
| Price / Sales ratio | x | 3.4 | 1.2 | 275.8% | |
| Avg P/E ratio | x | 25.1 | 4.0 | 627.3% | |
| P/CF ratio (eoy) | x | 21.8 | 3.5 | 614.5% | |
| Price / Book Value ratio | x | 4.8 | 0.8 | 577.2% | |
| Dividend payout | % | 22.6 | 3.6 | 635.3% | |
| Avg Mkt Cap | Rs m | 168,653 | 25,660 | 657.3% | |
| No. of employees | `000 | NA | 5.0 | 0.0% | |
| Total wages/salary | Rs m | 9,171 | 3,559 | 257.7% | |
| Avg. sales/employee | Rs Th | NM | 4,225.3 | - | |
| Avg. wages/employee | Rs Th | NM | 718.0 | - | |
| Avg. net profit/employee | Rs Th | NM | 1,295.9 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 49,915 | 20,945 | 238.3% | |
| Other income | Rs m | 1,645 | 1,302 | 126.4% | |
| Total revenues | Rs m | 51,561 | 22,247 | 231.8% | |
| Gross profit | Rs m | 8,482 | 7,948 | 106.7% | |
| Depreciation | Rs m | 1,006 | 810 | 124.2% | |
| Interest | Rs m | 671 | 193 | 347.5% | |
| Profit before tax | Rs m | 8,451 | 8,247 | 102.5% | |
| Minority Interest | Rs m | -114 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,606 | 1,823 | 88.1% | |
| Profit after tax | Rs m | 6,731 | 6,424 | 104.8% | |
| Gross profit margin | % | 17.0 | 37.9 | 44.8% | |
| Effective tax rate | % | 19.0 | 22.1 | 86.0% | |
| Net profit margin | % | 13.5 | 30.7 | 44.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 27,062 | 23,472 | 115.3% | |
| Current liabilities | Rs m | 15,324 | 7,287 | 210.3% | |
| Net working cap to sales | % | 23.5 | 77.3 | 30.4% | |
| Current ratio | x | 1.8 | 3.2 | 54.8% | |
| Inventory Days | Days | 67 | 92 | 72.1% | |
| Debtors Days | Days | 41 | 88 | 46.8% | |
| Net fixed assets | Rs m | 12,610 | 18,648 | 67.6% | |
| Share capital | Rs m | 239 | 365 | 65.5% | |
| "Free" reserves | Rs m | 34,490 | 34,525 | 99.9% | |
| Net worth | Rs m | 35,027 | 30,760 | 113.9% | |
| Long term debt | Rs m | 1,212 | 0 | - | |
| Total assets | Rs m | 54,387 | 43,031 | 126.4% | |
| Interest coverage | x | 13.6 | 43.7 | 31.1% | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 0.9 | 0.5 | 188.6% | |
| Return on assets | % | 13.6 | 15.4 | 88.5% | |
| Return on equity | % | 19.2 | 20.9 | 92.0% | |
| Return on capital | % | 24.9 | 27.4 | 90.6% | |
| Exports to sales | % | 12.9 | 0 | - | |
| Imports to sales | % | 3.1 | 0 | - | |
| Exports (fob) | Rs m | 6,461 | NA | - | |
| Imports (cif) | Rs m | 1,540 | NA | - | |
| Fx inflow | Rs m | 6,563 | 11,536 | 56.9% | |
| Fx outflow | Rs m | 3,012 | 2,939 | 102.5% | |
| Net fx | Rs m | 3,552 | 8,597 | 41.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 7,259 | 6,688 | 108.5% | |
| From Investments | Rs m | 1,864 | -6,122 | -30.5% | |
| From Financial Activity | Rs m | -9,273 | -509 | 1,821.7% | |
| Net Cashflow | Rs m | -150 | 66 | -227.3% | |
Share Holding
| Indian Promoters | % | 66.9 | 52.0 | 128.6% | |
| Foreign collaborators | % | 0.0 | 1.5 | - | |
| Indian inst/Mut Fund | % | 33.1 | 7.8 | 422.2% | |
| FIIs | % | 0.0 | 16.6 | - | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 0.0 | 26.0 | - | |
| Shareholders | 68,381 | 25,395 | 269.3% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALKEM LABORATORIES With: PFIZER GSK PHARMA STRIDES PHARMA SCIENCE WYETH LTD ABBOTT INDIA
Compare ALKEM LABORATORIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views on News
NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)
May 28, 2019 | Updated on May 28, 2019For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)
Nov 12, 2018 | Updated on Nov 12, 2018For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
More Views on NewsMost Popular
These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)
Jul 28, 2020When it comes to quality stocks, doing less is more.
Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)
Jul 29, 2020As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.
Large Opportunities Are Coming Our Way
Aug 5, 2020Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.
How to Buy Gold and Silver(Fast Profits Daily)
Jul 27, 2020In this video I'll show you how to buy bullion the right way.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2020
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
ALKEM LABORATORIES SHARE PRICE
Aug 7, 2020 (Close)
TRACK ALKEM LABORATORIES
- Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALKEM LABORATORIES
ALKEM LABORATORIES 8-QTR ANALYSIS
COMPARE ALKEM LABORATORIES WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.